Benign Prostatic Hyperplasia (BPH) Drugs Market Report

Global and Region Benign Prostatic Hyperplasia (BPH) Drugs Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Aug 03, 2022
  • PAGES：150
  • REPORT CODE：GMM1011914
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.

    The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.

    The report details the trend, potential and market size of Benign Prostatic Hyperplasia (BPH) Drugs market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Benign Prostatic Hyperplasia (BPH) Drugsmarket, defines the market attractiveness level of Benign Prostatic Hyperplasia (BPH) Drugs market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Benign Prostatic Hyperplasia (BPH) Drugs industry, describes the types of Benign Prostatic Hyperplasia (BPH) Drugs market, the applications of major players and the market size, and deeply analyzes the current situation of the global Benign Prostatic Hyperplasia (BPH) Drugs market and the development prospects and opportunities of Benign Prostatic Hyperplasia (BPH) Drugs industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Benign Prostatic Hyperplasia (BPH) Drugs market in Chapter 13.

    By Player:

    • Endo Pharmaceuticals

    • Bayer HealthCare

    • Sanofi

    • ADC Therapeutics

    • Foresee Pharmaceuticals

    • Eli Lilly

    • GlaxoSmithKline

    • Astellas Pharma

    • Valeant Pharmaceuticals

    • Bristol-Myers Squibb

    By Type:

    • Alpha-Blocker

    • Phosphodiesterase Type-5 Inhibitors

    • 5-Alpha-Reductase Inhibitors

    By End-User:

    • Men

    • Women

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Benign Prostatic Hyperplasia (BPH) Drugs Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Benign Prostatic Hyperplasia (BPH) Drugs Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Benign Prostatic Hyperplasia (BPH) Drugs Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Outlook to 2022

    • 7.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption (2017-2022)

    • 7.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption (2017-2022)

    • 7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption (2017-2022)

    • 7.4 China Benign Prostatic Hyperplasia (BPH) Drugs Consumption (2017-2022)

    • 7.5 Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption (2017-2022)

    • 7.6 India Benign Prostatic Hyperplasia (BPH) Drugs Consumption (2017-2022)

    • 7.7 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption (2017-2022)

    8 Region and Country-wise Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Outlook to 2028

    • 8.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2022-2028)

    • 8.2 United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2022-2028)

    • 8.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2022-2028)

    • 8.4 China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2022-2028)

    • 8.5 Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2022-2028)

    • 8.6 India Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2022-2028)

    • 8.7 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast (2022-2028)

    9 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Alpha-Blocker Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Phosphodiesterase Type-5 Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global 5-Alpha-Reductase Inhibitors Consumption and Growth Rate (2017-2022)

    • 9.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Men Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Women Consumption and Growth Rate (2017-2022)

    10 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook by Types and Applications to 2028

    • 10.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Alpha-Blocker Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global Phosphodiesterase Type-5 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global 5-Alpha-Reductase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Men Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Women Consumption Forecast and Growth Rate (2022-2028)

    11 Global Benign Prostatic Hyperplasia (BPH) Drugs Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Analysis

    • 14.1 Endo Pharmaceuticals

      • 14.1.1 Endo Pharmaceuticals Company Details

      • 14.1.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.2 Bayer HealthCare

      • 14.2.1 Bayer HealthCare Company Details

      • 14.2.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.3 Sanofi

      • 14.3.1 Sanofi Company Details

      • 14.3.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.4 ADC Therapeutics

      • 14.4.1 ADC Therapeutics Company Details

      • 14.4.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.5 Foresee Pharmaceuticals

      • 14.5.1 Foresee Pharmaceuticals Company Details

      • 14.5.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.6 Eli Lilly

      • 14.6.1 Eli Lilly Company Details

      • 14.6.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.7 GlaxoSmithKline

      • 14.7.1 GlaxoSmithKline Company Details

      • 14.7.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.8 Astellas Pharma

      • 14.8.1 Astellas Pharma Company Details

      • 14.8.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.9 Valeant Pharmaceuticals

      • 14.9.1 Valeant Pharmaceuticals Company Details

      • 14.9.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • 14.10 Bristol-Myers Squibb

      • 14.10.1 Bristol-Myers Squibb Company Details

      • 14.10.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Benign Prostatic Hyperplasia (BPH) Drugs

    • Figure Benign Prostatic Hyperplasia (BPH) Drugs Picture

    • Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Country (2017-2022)

    • Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Benign Prostatic Hyperplasia (BPH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Benign Prostatic Hyperplasia (BPH) Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Alpha-Blocker Consumption and Growth Rate (2017-2022)

    • Figure Global Phosphodiesterase Type-5 Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global 5-Alpha-Reductase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Men Consumption and Growth Rate (2017-2022)

    • Figure Global Women Consumption and Growth Rate (2017-2022)

    • Figure Global Alpha-Blocker Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Phosphodiesterase Type-5 Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global 5-Alpha-Reductase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Men Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Women Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Benign Prostatic Hyperplasia (BPH) Drugs Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Benign Prostatic Hyperplasia (BPH) Drugs Export by Region (Top 5 Countries) (2017-2028)

    • Table Endo Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table Bayer HealthCare (Foundation Year, Company Profile and etc.)

    • Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table ADC Therapeutics (Foundation Year, Company Profile and etc.)

    • Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table Foresee Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table Astellas Pharma (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table Valeant Pharmaceuticals (Foundation Year, Company Profile and etc.)

    • Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product and Service

    • Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US